Novavax Jumps After Starting Covid-19 Vaccine Study
- Vaccine to be tested on 130 healthy volunteers in Australia
- Biotech’s vaccine is one of an estimated 10 being tested
Three potential coronavirus vaccines are seen at Novavax labs in Rockville, Maryland on March 20.
Photographer: Andrew Caballero-Reynolds/AFP via Getty Images
This article is for subscribers only.
Novavax Inc. jumped at much as 18% on Tuesday after initiating testing of its coronavirus vaccine candidate in people. The biotech anticipates providing a first look in July at what sort of immune responses are generated.
In the first part of the study, 130 healthy adult volunteers at two sites in Australia will get two doses of NVX-CoV2373, the biotech’s experimental vaccine. If the initial results look promising, the company plans to quickly move into the second phase of the trial, which would expand testing to other countries and age groups outside of 18 to 59.